With Oracle Health Clinical AI Agent integrated into Oracle Health Foundation EHR, physicians at MSRHC will be able to use natural conversation during patient encounters while the system automatically drafts structured clinical notes in the background. Providers then review and approve the documentation, which helps reduce time spent on manual data entry and supports efforts to address physician burnout. Oracle Health Seamless Exchange will help MSRHC securely aggregate data from national and local exchange ...

Revenue Performance - Rafael Holdings reported a 100% increase in product revenue for the Healthcare segment, reaching approximately $0.2 million for the three months ended October 31, 2025, compared to $0 for the same period in 2024[268]. - The Infusion Technology segment reported a 100% decrease in revenue, falling to $0 for the three months ended October 31, 2025, compared to $51,000 in the same period in 2024[271]. - The Real Estate segment generated rental income of $56,000 from third parties, reflecting a 12% increase compared to $50,000 in the prior year[273]. - Revenue from tenants located in Israel represented 36% of consolidated revenues for the three months ended October 31, 2025, down from 60% in 2024[293]. Expenses - Research and development expenses surged by 545% to $7.5 million for the Healthcare segment in the three months ended October 31, 2025, primarily due to the consolidation of Cyclo's expenses[267]. - General and administrative expenses for the Healthcare segment increased by 20% to $2.8 million, largely due to the inclusion of Cyclo's expenses[269]. - General and administrative expenses in the Real Estate segment decreased by 53% to $57,000, primarily due to reduced real estate taxes[273]. - Consolidated net loss for the three months ended October 31, 2025, was $9.8 million, a 6% increase from the net loss of $9.2 million in the same period of 2024[274]. - Loss from operations increased by 164% to $10.1 million for the three months ended October 31, 2025, compared to a loss of $3.8 million in 2024[274]. - Interest income decreased by 30% to $0.4 million for the three months ended October 31, 2025, compared to $0.6 million in 2024[274]. Cash Flow and Working Capital - Cash and cash equivalents decreased by 14% to $45.5 million as of October 31, 2025, down from $52.8 million on July 31, 2025[282]. - Working capital decreased by 20% to $36.2 million as of October 31, 2025, compared to $45.1 million on July 31, 2025[282]. - Cash used in operating activities was $6.8 million for the three months ended October 31, 2025, a 124% increase from $3.0 million used in the same period of 2024[284]. - Cash flows from investing activities for the three months ended October 31, 2025, included a purchase of preferred shares for $0.5 million[286]. Assets and Holdings - Total assets decreased by 8% to $105.4 million as of October 31, 2025, from $114.1 million on July 31, 2025[282]. - Rafael Holdings holds a 95% interest in LipoMedix and a 67% interest in Cornerstone, with ongoing evaluations of these holdings to focus resources on core assets[260][262]. Strategic Developments - The FDA granted substantial equivalence determination for the VECTR System, which is designed for minimally invasive surgeries, marking a significant milestone for Rafael Medical Devices[263]. - The merger with Cyclo was completed on March 25, 2025, making Cyclo a wholly-owned subsidiary and enhancing the company's product pipeline[259]. - The company is strategically focusing on the development of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1, with ongoing Phase 3 clinical trials[257].

Financial Performance - Rafael Holdings reported a net loss of $9.8 million, or $0.19 per share, for the first quarter of fiscal 2026, compared to a net loss of $9.0 million, or $0.37 per share, in the same period last year[5]. - Total revenues for the quarter were $240,000, up from $128,000 in the same quarter of the previous year[15]. - Operating loss for the quarter was $10.1 million, compared to an operating loss of $3.8 million in the prior year[15]. - General and administrative expenses rose to $2.8 million for the quarter, compared to $2.5 million in the same period last year[7]. Research and Development - Research and development expenses increased to $7.5 million for the three months ended October 31, 2025, from $1.3 million in the prior year, primarily due to the consolidation of Cyclo Therapeutics' expenses following its acquisition[6]. - The company is progressing in its pivotal Phase 3 TransportNPC™ study for Trappsol Cyclo™, which is aimed at treating Niemann-Pick Disease Type C1[3]. Cash and Assets - Cash and cash equivalents as of October 31, 2025, were $45.5 million, down from $52.8 million as of July 31, 2025[4]. - Total current assets decreased to $48.3 million as of October 31, 2025, from $56.7 million as of July 31, 2025[12]. - The accumulated deficit increased to $242.1 million as of October 31, 2025, from $232.3 million as of July 31, 2025[12]. - Total equity attributable to Rafael Holdings decreased to $85.2 million as of October 31, 2025, from $94.4 million as of July 31, 2025[12].

NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025. “We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol® Cyclo™ ...

Group 1 - The Raytheon-Rafael Protection Systems (R2S) joint venture has secured a $1.25 billion contract to supply Israel with Tamir surface-to-air missiles, marking a significant milestone for both companies [1][3] - A new facility in East Camden, Arkansas, was established with a $33 million investment to support the production of Iron Dome interceptors, specifically the Tamir missiles for both the Iron Dome and its U.S. variant, SkyHunter [2][3] - The Iron Dome system, operational since 2011, has demonstrated a success rate exceeding 95% in intercepting threats, showcasing its effectiveness in combat [3] Group 2 - Raytheon, as part of RTX, is a leading provider of defense solutions, focusing on integrated air and missile defense, smart weapons, and advanced sensors [5][6] - Rafael Advanced Defense Systems Ltd. is one of Israel's largest defense companies, providing a wide range of high-tech defense systems for various applications [4] - RTX, the world's largest aerospace and defense company, reported sales exceeding $80 billion for 2024 and employs over 185,000 people globally [6]

Financial Performance - Rafael Holdings reported a 100% increase in product revenue for the Healthcare segment, reaching approximately $515 thousand for the year ended July 31, 2025, compared to $0 in the previous year[466]. - General and administrative expenses rose by 58% to $13.165 million in 2025, primarily due to the consolidation of Cyclo's expenses following the merger[467]. - Research and development expenses surged by 243% to $12.568 million, largely driven by the inclusion of Cyclo's R&D costs post-merger[468]. - The Infusion Technology segment experienced a 74% decline in revenue, dropping to $93 thousand from $355 thousand in 2024[470]. - An impairment charge of $3.1 million was recorded for the Infusion Technology segment's goodwill due to a decline in estimated fair value[471]. - Consolidated loss from operations improved by 72% to $(29.2) million in 2025 from $(102.6) million in 2024[474]. - Net loss attributable to Rafael Holdings, Inc. decreased by 11% to $(30.5) million in 2025 from $(34.4) million in 2024[474]. Cash Flow and Assets - Cash and cash equivalents surged by 1,873% to $52.8 million as of July 31, 2025, up from $2.7 million in 2024[484]. - Cash used in operating activities increased by 143% to $(18.9) million in 2025, compared to $(7.8) million in 2024[486]. - Cash provided by investing activities rose significantly to $44.0 million in 2025, compared to cash used of $(10.8) million in 2024[488]. - Financing activities generated $24.8 million in 2025, a substantial increase from $(0.2) million in 2024[490]. - Total assets grew by 18% to $114.1 million in 2025, up from $96.8 million in 2024[484]. Investments and Subsidiaries - Rafael Holdings holds a 67% interest in Cornerstone Pharmaceuticals following a restructuring, which has become a consolidated subsidiary[460]. - The company invested approximately $582,000 in Rafael Medical Devices in February 2025, maintaining a 73% equity interest[461]. - The merger with Cyclo was completed on March 25, 2025, allowing for the consolidation of Cyclo's financial results[456]. - Rafael Holdings aims to expand its investment portfolio through strategic investments addressing high unmet medical needs[454]. Revenue Sources - Real Estate segment rental revenue increased by 13% to $197,000 for the year ended July 31, 2025, compared to $174,000 in 2024[473]. - Revenue from tenants located in Israel accounted for 34% of consolidated revenues for the year ended July 31, 2025, down from 44% in 2024, with all revenues in currencies other than the U.S. Dollar[503]. Impairment and Goodwill - The company recorded a goodwill impairment charge of $3.1 million for the Infusion Technology segment, representing a full write-off of the goodwill balance associated with this operating segment[499]. - Unrealized loss on investment in Cyclo was $(5.1) million for the year ended July 31, 2025, compared to a gain of $37,000 in 2024[477]. - The company assesses goodwill for impairment annually or more frequently if triggering events occur, using both qualitative and quantitative assessments[498]. Regulatory and Clinical Developments - The FDA granted substantial equivalence determination for the VECTR System, a product of Rafael Medical Devices, for use in minimally invasive surgeries[461]. - Clinical trial accruals are estimated based on the progress of specific tasks and unbilled patient visits related to third-party vendor services[501]. - The company does not have any off-balance sheet arrangements that could materially affect its financial condition or results of operations[502].

Financial Performance - For the fourth quarter ended July 31, 2025, Rafael Holdings reported a net loss of $12.1 million, or $0.28 per share, compared to a net loss of $4.5 million, or $0.19 per share in the same period last year, reflecting an increase in net loss due to the consolidation of Cyclo Therapeutics' expenses[4] - For the full fiscal year 2025, Rafael Holdings recorded a net loss of $30.5 million, or $1.04 per share, an improvement from a net loss of $34.4 million, or $1.45 per share in the previous year[7] - The operating loss for the three months ended July 31, 2025, was $(12,763,000), compared to $(3,845,000) in the same period of 2024, reflecting a deterioration of 231.5%[19] - Consolidated net loss attributable to Rafael Holdings, Inc. was $(12,094,000) for the three months ended July 31, 2025, compared to $(4,468,000) in Q3 2024, an increase of 170.5%[19] - The loss before income taxes for the year ended July 31, 2025, was $(33,196,000), compared to $(67,261,000) in 2024, showing an improvement of 50.7%[19] Expenses - Research and development expenses for the fourth quarter were $7.5 million, up from $1.5 million in the prior year, primarily due to the inclusion of Cyclo's spending following its acquisition[5] - General and administrative expenses increased to $5.5 million for the fourth quarter, compared to $2.3 million in the same period last year, attributed to expenses from Cyclo and the consolidation of Cornerstone and Day Three[6] - Full year research and development expenses totaled $12.8 million, compared to $4.2 million in the prior year, reflecting increased spending at Cyclo following its acquisition[8] - General and administrative expenses for the full year were $13.8 million, up from $8.9 million in the previous year, driven by the acquisition-related expenses[9] - General and Administrative (G&A) expenses rose significantly to $5,497,000 in Q3 2025 from $2,330,000 in Q3 2024, an increase of 136.7%[19] - Research and Development (R&D) expenses surged to $7,547,000 in Q3 2025 compared to $1,543,000 in Q3 2024, marking a substantial increase of 388.5%[19] Revenue - Revenues for the three months ended July 31, 2025, increased to $350,000 from $165,000 in the same period of 2024, representing a growth of 112.1%[19] - Total revenues for the year ended July 31, 2025, were $917,000, up from $637,000 in 2024, representing a year-over-year increase of 43.9%[19] Cash Position - As of July 31, 2025, Rafael Holdings had cash and cash equivalents of $52.8 million, bolstered by a $25 million rights offering completed in June 2025[3] Strategic Initiatives - The company is advancing its pivotal Phase 3 TransportNPC™ study for Trappsol Cyclo™, aimed at treating Niemann-Pick Disease Type C1, which is a rare genetic disorder[2] - The acquisition of Cyclo Therapeutics in March 2025 has led to the consolidation of its expenses and activities, impacting the financial results significantly[4] - The company is positioned to explore additional opportunities following the enhancement of its financial position through the rights offering[2] Share Information - Basic and diluted loss per share increased to $(0.28) in Q3 2025 from $(0.19) in Q3 2024, indicating a decline of 47.4%[19] - The weighted average number of shares used in the calculation of loss per share increased to 43,011,360 in Q3 2025 from 23,916,839 in Q3 2024, an increase of 79.8%[19] Interest Income - The company reported a significant increase in interest income, reaching $1,996,000 for the year ended July 31, 2025, compared to $2,383,000 in 2024, a decrease of 16.1%[19]

Core Insights - The pivotal Phase 3 clinical trial for Trappsol Cyclo™ is ongoing, with positive recommendations from the Data Monitoring Committee [1][2] - The company successfully closed a $25 million rights offering, enhancing its financial position to support the Trappsol Cyclo™ program and other opportunities [2] - Rafael Holdings reported a net loss of $12.1 million for Q4 FY 2025, an increase from a net loss of $4.5 million in the same period last year, primarily due to the consolidation of Cyclo Therapeutics' expenses [4][5] Financial Performance - As of July 31, 2025, the company had cash and cash equivalents of $52.8 million, following the $25 million rights offering closed in June 2025 [3] - For the three months ended July 31, 2025, research and development expenses rose to $7.5 million from $1.5 million year-over-year, reflecting increased spending at Cyclo Therapeutics [5] - General and administrative expenses for the same period were $5.5 million, up from $2.3 million in the prior year, also due to the inclusion of Cyclo's expenses [6] Yearly Overview - For the full fiscal year 2025, Rafael Holdings recorded a net loss of $30.5 million, an improvement from a net loss of $34.4 million in the previous year [7] - Research and development expenses for the full year were $12.8 million, compared to $4.2 million in the prior year, driven by the acquisition of Cyclo Therapeutics [8] - General and administrative expenses for the full year increased to $13.8 million from $8.9 million, attributed to the consolidation of Cyclo and other entities [9][10] Company Background - Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals, with its lead candidate Trappsol® Cyclo™ aimed at treating Niemann-Pick Disease Type C1 [11]

Core Points - Rafael Holdings, Inc. announced the passing of Lead Independent Director Stephen Greenberg and appointed Alan Grayson to the Board of Directors [1][3] - Markus Sieger, an existing Board member, has been elected as Lead Independent Director and will chair the Audit Committee [1][4] Company Overview - Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals and holding interests in clinical and early-stage companies [5] - The company's lead candidate, Trappsol® Cyclo™, is currently undergoing a pivotal Phase 3 clinical trial for the treatment of Niemann-Pick Disease Type C1 [5]

Core Viewpoint - Terra Clean Energy Corp has entered into definitive agreements to acquire up to a 100% interest in the Wheel Anne Claims and the Green Vein Mesa Claims located in Emery County, Utah, demonstrating the company's commitment to expanding its portfolio of uranium assets [1][2]. Acquisition Details - The agreements require cash payments, share issuances, and exploration expenditures to earn interests in the claims [2]. - For the Wheal Anne Claims, to earn a 20% interest, the company must pay USD$20,000 and issue 500,000 common shares, along with incurring USD$100,000 in exploration expenditures within the first year [3]. - The structure for earning interests in the Wheal Anne Claims includes additional payments and share issuances over a five-year period, culminating in a total cash payment of USD$233,333 and issuance of 2,500,000 common shares for a 100% interest [3]. - The Green Vein Mesa Claims require a similar structure, starting with a USD$10,000 cash payment and 250,000 common shares for a 20% interest, with total payments and share issuances reaching USD$116,667 and 1,250,000 common shares for a 100% interest over four years [4][5]. Regulatory and Compliance - The definitive agreements are subject to regulatory approvals, including from the Canadian Securities Exchange, with the "Effective Date" being the date all approvals are received [6]. - All securities issued in connection with these agreements will be subject to a four-month plus one day hold period from the date of issuance [7]. Marketing Agreements - Terra Clean has engaged Green Crescent Capital for marketing services, with a one-time fee of USD$5,000 for a one-month term [8]. - The company has also contracted OTCWagon for a 38-day market awareness program, with a fee of C$7,500 [9]. Company Overview - Terra Clean Energy is a Canadian-based uranium exploration and development company, currently developing the South Falcon East uranium project in Saskatchewan and past producing uranium mines in Emery County, Utah [10].